Home › Colon Cancer › Massachusetts
Colon Cancer clinical trials in Massachusetts
24 studies for Colon Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07127874Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
- Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07222800Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07629960A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Massachusetts General Hospital, Boston
- Oncura Health, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07284849Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 to 50 · All sexes · Updated Sep 11, 2026 · NCT06202183Resilience and Equity in Aging, Cancer, and Health (REACH)
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 65 and older · All sexes · Updated Sep 10, 2026 · NCT04674267Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- Massachusetts General Hospital Cancer Center, Boston
- Boston Veteran's Affairs Medical Center, Jamaica Plain
Recruiting
Ages 45 to 70 · All sexes · Updated Sep 2, 2026 · NCT05080673Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Beverly Hospital, Beverly
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton
- and 7 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT05174169Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT07675967A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07458347Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT06835569Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT06040541A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases
- Dana-Farber Cancer Institute, Boston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT02172651Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
- Dana Farber Cancer Institute, Boston
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 11, 2026 · NCT00843375Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06239194Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT05773144Building Connections
- Disparities Research Unit, Massachusetts General Hospital, Boston
Recruiting
Ages 18 to 75 · All sexes · Updated Nov 18, 2025 · NCT07091032Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
- Codman Square Health Center, Boston
- Brockton Neighborhood Health Center, Brockton
- East Boston Neighborhood Health Center, East Boston
- and 1 more
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 14, 2025 · NCT05524428SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.